In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.
A staggering 64% of adults in England are classed as either overweight or obese according to the most recent NHS figures. And ...
The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
For once, the U.K.’s health technology assessment body, the National Institute of Health and Care Excellence (NICE), has no reservations about the cost effectiveness of a new drug and is recommending ...
(The Hill) – Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
A new study suggests weight loss drugs like Ozempic and Mounjaro could provide a promising new treatment for substance use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback